Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Merit Medical Systems manufactures and distributes single-use medical devices for interventional and diagnostic procedures, with primary focus on cardiovascular, peripheral vascular, and interventional oncology markets. The company operates manufacturing facilities in Utah, Ireland, and Mexico, serving hospitals and ASCs globally through a direct sales force in the US and distributor network internationally. Stock performance is driven by procedural volumes in interventional cardiology/radiology, new product adoption rates, and operating margin expansion through manufacturing efficiency.
Merit generates revenue through high-volume sales of disposable interventional devices used in minimally invasive procedures. Pricing power derives from procedural standardization (hospitals stock specific kits), regulatory barriers (510k clearances, CE marks), and switching costs once physicians are trained on specific devices. Gross margins of ~49% reflect mix of commodity products (basic catheters) and differentiated technologies (embolization microspheres, specialized delivery systems). The company competes on procedural efficiency and cost-per-procedure economics rather than premium pricing, targeting value-conscious hospital systems.
US interventional procedure volumes - particularly cardiac catheterizations, peripheral vascular interventions, and interventional oncology procedures which drive device utilization
New product launch momentum and market share gains in embolization (competing with Boston Scientific, Terumo) and hemostasis (competing with Teleflex, Terumo)
Gross margin trajectory driven by manufacturing efficiency, product mix shift toward higher-margin embolization/oncology devices, and raw material cost inflation
International revenue growth, particularly in Europe and Asia-Pacific where distributor partnerships and direct expansion drive penetration
M&A activity - Merit has historically grown through tuck-in acquisitions of complementary device portfolios
Reimbursement pressure from CMS and commercial payers reducing procedure payments, which forces hospitals to demand lower device pricing and threatens gross margins
Regulatory pathway changes - FDA increased scrutiny of 510(k) clearances or reclassification of devices to PMA standard would slow new product launches and increase development costs
Shift toward value-based care and bundled payments incentivizes hospitals to consolidate vendors and negotiate aggressive pricing, benefiting larger competitors (Medtronic, Boston Scientific) with broader portfolios
Market share erosion to larger, better-capitalized competitors (Boston Scientific, Medtronic, Becton Dickinson) who can offer bundled contracts, clinical support, and integrated technologies
Commoditization of core cardiovascular products (angiography kits, basic catheters) as patents expire and low-cost Asian manufacturers enter US/European markets
Dependence on distributor relationships in international markets creates execution risk and margin pressure versus direct sales models
Moderate leverage with Debt/Equity of 0.57 and net debt estimated ~$200-250M - manageable but limits financial flexibility for large acquisitions or economic downturn
Working capital intensity (Current Ratio 4.34 suggests high inventory) creates cash conversion risk if demand slows or product mix shifts
Acquisition integration risk - historical M&A strategy requires successful integration of manufacturing, sales, and regulatory systems to achieve synergies
moderate - Interventional procedures are semi-discretionary with 60-70% driven by urgent/emergent cases (STEMI, stroke, cancer) that are recession-resistant, but 30-40% are elective procedures (stable angina, peripheral claudication) that can be deferred during economic stress. Hospital capital budgets and staffing levels also affect procedure scheduling capacity. GDP growth correlates with elective procedure volumes and hospital purchasing patterns, but the relationship is dampened by aging demographics (Medicare-driven demand) and clinical guideline expansion favoring minimally invasive techniques.
Rising rates have modest negative impact through two channels: (1) higher borrowing costs on $250M+ debt balance (mix of fixed/variable), though Debt/Equity of 0.57 is manageable, and (2) valuation multiple compression as med-tech stocks typically trade on forward P/E and rising discount rates reduce present value of future earnings. Demand side is largely insulated as procedures are reimbursed by Medicare/commercial insurance, not consumer-financed. Hospital system capital spending can be constrained by higher financing costs, but Merit's consumables model is less affected than capital equipment vendors.
Minimal direct credit exposure. Revenue is primarily from hospital systems with stable payment (Medicare/Medicaid reimbursement, commercial insurance), not consumer credit-dependent. Receivables risk is low given customer base of investment-grade health systems. However, hospital financial stress during credit tightening can lead to pricing pressure, extended payment terms, and inventory destocking.
value - Stock trades at 2.8x P/S and 14.4x EV/EBITDA, below historical medtech averages, attracting value investors betting on margin expansion and multiple re-rating. Recent 27% one-year decline creates contrarian opportunity if procedural volumes stabilize and operational execution improves. 5% FCF yield provides downside support. Growth investors are less attracted given single-digit EPS growth, but improving organic growth and M&A could shift sentiment.
moderate - Medical device stocks typically exhibit lower volatility than broader market (beta ~0.8-1.0) due to recurring revenue from hospital procedures and diversified product portfolio. However, Merit's mid-cap size ($4.3B) and exposure to elective procedures creates more volatility than large-cap peers. Recent 13% three-month decline suggests elevated volatility during market uncertainty or procedural volume concerns.
